Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art

Toh, Zheng Quan; Licciardi, Paul V.; Fong, James; Garland, Suzanne M.; Tabrizi, Sepehr N.; Russell, Fiona; Mulholland, E. Kim

doi:10.1016/j.vaccine.2015.07.102

Cited by 20 publications

(20 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This review evaluated studies incorporating a three-dose schedule. Reduced dose arms in vaccine trials have demonstrated non-inferior seropositivity to vaccine genotypes and similar vaccine efficacy [33,34], resulting in a recommendation for a two dose schedule to be adopted worldwide [35]. However, reduced seropositivity to HPV31 has been demonstrated for less than three doses [36], which is likely to be a factor in the reduced vaccine efficacy observed against non-vaccine genotypes HPV31 and HPV45 in a post-hoc analysis of Cervarix® trial data [37].…”

Section: Discussionmentioning

confidence: 99%

Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis

Bissett

Godi

Jit

et al. 2017

Vaccine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis

Bissett

Godi

Jit

et al. 2017

Vaccine

View full text Add to dashboard Cite

show abstract

“…In addition, it is sufficient to administer 2 doses of HPV vaccine 6 months apart in this age group compared to 3 doses to females older than 15 y of age. 27 However, in many cases and for many different reasons, the vaccine may be administered during a woman's fertile life and the risk of inadvertent vaccination during or immediately prior to pregnancy exists. This review suggests that the risk of AE during pregnancy is unrelated to HPV vaccination before or during pregnancy.…”

Section: Discussionmentioning

confidence: 99%

Is HPV vaccination in pregnancy safe?

Bonde

Joergensen

Lamont

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Millions of doses of HPV vaccine have been administered globally. Inadvertent administration of HPV vaccine during pregnancy occurs given that the main recipients of the vaccine are fertile young women, who might be unaware of their pregnancy at the time of their vaccination. To investigate the subject of HPV vaccine and pregnancy , the databases of PubMed and Embase were searched to find the relevant literature published in English within the last 10 y. Most of the evidence pertaining to fetal adverse events following HPV vaccination relates to spontaneous miscarriage. None of the relevant studies found any significantly increased rate of spontaneous abortion in the overall analyses. There was no indication of other HPV vaccine-associated adverse events in pregnancy or immediately post-conception.

show abstract

“…Third, it is likely that newer vaccines, active against multiple HPV types, will provide even greater levels of protection [27]. It has also been reported that two doses of HPV vaccine are equally effective in producing immunity as three doses [28]. This might further reduce the cost, and subsequently increase the cost-effectiveness of the vaccination, as demonstrated in a cost-effectiveness study in the UK [29], As our study did not take into account these aspects, future studies might be necessary to investigate these factors for Lao PDR.…”

Section: Discussionmentioning

confidence: 99%

The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach

Chanthavilay

Reinharz

Mayxay

et al. 2016

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundCervical cancer, a preventable disease, is the third leading cause of cancer morbidity and mortality in the Lao People’s Democratic Republic (Lao PDR). Since many cervical cancers are linked to human papilloma virus (HPV) infection, vaccination against this virus may lead to a reduction in these types of cancer. The study described here is the first to compare the cost-effectiveness of different HPV vaccination options in Lao PDR.MethodsA dynamic compartment model was created. The model included routine screening activities already in place, as well as theoretical interventions that included a 10-year old girl-only vaccination programme combined with/without a 10-year old boy vaccination programme and/or a catch-up component. The simulation was run over 100 years. In base case analyses, we assumed 70 % vaccination coverage with lifelong protection and 100 % efficacy against HPV types 16/18. The outcomes of interest were the incremental cost per Disability-Adjusted Life Year (DALY) averted.ResultsIn base case analyses, according to the WHO definition of cost-effectiveness thresholds, vaccinating 10-year-old girls was very cost-effective. Adding a catch-up vaccination element for females aged 11–25 years was also very cost-effective, costing 1559 international dollars (I$) per DALY averted. Increasing the age limit of the catch-up vaccination component to 75 years old showed that this remained a cost-effective option (I$ 5840 per DALY averted). Adding a vaccination programme for 10-year-old boys was not found to be cost-effective unless a short time simulation (30 years or less) was considered, along with a catch-up vaccination component for both males and females.ConclusionsAdding a catch-up female vaccination component is more attractive than adding a 10-year-old boy vaccination component.Electronic supplementary materialThe online version of this article (doi:10.1186/s12913-016-1662-5) contains supplementary material, which is available to authorized users.

show abstract

Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art

Cited by 20 publications

References 61 publications

Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis

Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis

Is HPV vaccination in pregnancy safe?

The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach

Contact Info

Product

Resources

About